Manufacturing & Packaging

Facility, with expected completion of 2025, will specialize in mRNA-based therapies

As a result of new production area, India site’s total production capacity rises from 3 to 4.5 billion doses

Investment will grow manufacturing capabilities at Winchester site

East Syracuse site will serve as a hub for company’s US biologics CDMO business

Among functions, 80,000 square-foot space will house a 'Center of Excellence'

Location will feature aseptic fill-finish technology

Among efforts, part of center’s focus revolves providing tools for product commercialization

Facility will feature biologic manufacturing, along with late-stage research and clinical development of cancer medicines

Expected to be ready by mid-2024

Deal for New Jersey cell therapy site totals $44.5 million

Commercial-scale center will cost $650 million, featuring 144,000 liters of biomanufacturing capacity

Deal adds biopharma services to its capabilities

Will address biologics drug substance and drug product manufacturing services

Factory will reportedly provide capability of manufacturing 3-4 vaccines simultaneously

Biotech company hopes to tackle challenges surrounding therapeutics

Expansion expected to double batch capacity

Includes a 36,000-square-foot addition to Charlottetown location

Includes 100,000 square feet of controlled ambient storage

Campus will feature a CDMO, over 1,000,000 square feet of floor space

Company strives to provide essential medicines that are in low supply

CDMO will invest up to $160 million toward manufacturing of therapies and vaccines, including mRNA

Features growth of cold storage, visual inspections capacity

Collective project expected to enhance the manufacturing supply chain for ATMPs within the UK

Will have capability of producing 300 million COVID-19 vaccines for Africa annually

How CDMOs will lead the way toward true cloud lab enablement

Site construction is part of a 10-year agreement with the Australian government

It has become critical to provide real-time accurate labeling information to labeling teams and healthcare providers as soon as a product change is approved by regulators. IQVIA‘s Cham Williams discusses the technology needed to support this shift and how these new solutions will minimize risks associated with regulatory compliance and increase patient safety.

Accreditation further extends CDMO's viral vector manufacturing capacity

Acquisition expected to be finalized in April

Survey conducted by HDA reveals thought process of manufacturers, distributors, and 3PLs